The brain drug developer is continuing a trial despite a recommendation it be stopped for futility. Elsewhere, Eli Lilly ...

The deal comes amid an uptick in so-called SPAC deals, which had fallen out of favor due to poor returns and increased ...

RBC Capital analyst Leonid Timashev maintained a Buy rating on Cytokinetics (CYTK – Research Report) yesterday and set a price target of ...

Following Pfizer’s acquisition, Biohaven’s valuation skyrocketed under Vlad Coric. Find out why BHVN stock’s growth potential ...

Phase 3 registrational trials evaluating petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC and petosemtamab monotherapy in ...

Biohaven (NYSE:BHVN – Get Free Report) is expected to be issuing its quarterly earnings data before the market opens on Thursday, March 6th. Analysts expect the company to announce earnings of ($1.56) ...

Amy Candido joins Simpson Thacher after more than three years as a partner at Wilson Sonsini Goodrich & Rosati.

The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) for troriluzole for the treatment of adults with spinocerebellar ataxia (SCA).

About a dozen drugmakers are developing new weight-loss treatments aimed at preserving muscle, and industry analysts, ...

New weight-loss treatments are being developed to preserve or increase muscle mass while shedding pounds. Companies like Eli Lilly, Regeneron, and Roche are focusing on therapies that target proteins ...